Although improvements in the chemotherapy modalities for pancreatic cancer have been
realized, pancreatic cancer remains one of the most lethal malignancies. New-generation …

Background Pancreatic cancer is one of the most aggressive and intractable malignant
tumors, and most deaths from pancreatic cancer are related to metastases. It has been …

Immunotherapy using anti‐PD‐1/PD‐L1 antibodies for several types of cancer has received
considerable attention in recent decades. However, the molecular mechanism underlying …

Despite recent improvements in treatment modalities, pancreatic cancer remains a highly
lethal tumor with mortality rate increasing every year. Poly (ADP-ribose) polymerase (PARP) …

Abstract Background The PD-1/PD-L1 checkpoint is a central mediator of
immunosuppression in the tumor immune microenvironment (TME) and is primarily …

Pancreatic cancer is the seventh leading cause of death in developed countries and it still
has a poor prognosis despite intense research in the last 20 years. Immunotherapy is a …

Background: Programmed cell death ligand 1 (PD-L1) expression was reported to be
associated with poor prognosis in various solid tumors. However, the prognosis value of PD …

Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis
remains poor. Therefore, the development of novel therapeutic strategies is urgently …

PD‑L1 inhibitors are widely used in tumor immunotherapy, but their mechanism in colorectal
cancer remains unclear. The present study aimed to investigate the mechanisms underlying …

Abstract Background/Abstract: PD-L1 has been an important target of cancer
immunotherapy. We have showed that in human gastric cancer tissues, over-expression of …